Medulloblastoma - Pipeline Review, H2 2016

Date: December 21, 2016
Pages: 95
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: MF7DB68C5DBEN
Leaflet:

Download PDF Leaflet

Medulloblastoma - Pipeline Review, H2 2016
Medulloblastoma - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Medulloblastoma – Pipeline Review, H2 2016, provides an overview of the Medulloblastoma (Oncology) pipeline landscape.

Medulloblastoma is the most common malignant brain tumor in children. Medulloblastoma by definition occur in the cerebellum, which is the part of brain located at the base of the skull, just above the brainstem. Symptoms associated with a medulloblastoma include headaches in the morning that improve as the day goes on, recurrent vomiting and difficulty walking and with balance. Medulloblastoma can spread to other areas of the central nervous system. Treatment includes options such as chemotherapy, surgery, biological therapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Medulloblastoma – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Medulloblastoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Medulloblastoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Medulloblastoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 4, 3 and 12 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively.

Medulloblastoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Medulloblastoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Medulloblastoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Medulloblastoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Medulloblastoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Medulloblastoma (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Medulloblastoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Medulloblastoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Medulloblastoma Overview
Therapeutics Development
Pipeline Products for Medulloblastoma - Overview
Pipeline Products for Medulloblastoma - Comparative Analysis
Medulloblastoma - Therapeutics under Development by Companies
Medulloblastoma - Therapeutics under Investigation by Universities/Institutes
Medulloblastoma - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Medulloblastoma - Products under Development by Companies
Medulloblastoma - Products under Investigation by Universities/Institutes
Medulloblastoma - Companies Involved in Therapeutics Development
Bayer AG
DelMar Pharmaceuticals Inc
Ignyta Inc
IMPACT Therapeutics Inc
Lipocure Ltd
MacroGenics Inc
NewLink Genetics Corp
Novogen Ltd
Progenics Pharmaceuticals Inc
Stemline Therapeutics Inc
ThromboGenics NV
VBI Vaccines Inc
Vyriad Inc
Medulloblastoma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(topotecan hydrochloride + vincristine sulfate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dianhydrogalactitol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Edotreotide Labeled Yttrium 90 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMP-5471 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
indoximod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
irinotecan hydrochloride + TBio-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Target IL13Ralpha2 and CD3 for Melanoma, Glioblastoma Multiforme and Medulloblastoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Target ROR1 and CD3 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nifurtimox - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nifurtimox SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oncolytic Virus to Target CD46 for Brain Tumor and Recurrent Medulloblastoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
p28 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pyrvinium pamoate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SL-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit STAT3 for Medulloblastoma and Glioblastoma Multiforme - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
taladegib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
THR-317 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Trilexium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VBI-1901 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vimo-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VMY-1103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Medulloblastoma - Dormant Projects
Medulloblastoma - Product Development Milestones
Featured News & Press Releases
Nov 10, 2016: VBI Vaccines to Present at the Society of Neuro-Oncology Annual Meeting
Oct 13, 2016: DelMar Pharmaceuticals Announces Upcoming Scientific Conference Presentations
Oct 05, 2016: VBI Vaccines to Present at the World Vaccine Congress Europe
Aug 29, 2016: VBI Vaccines to Present at the Immuno-Oncology Summit
Jun 16, 2016: VBI Vaccines Announces Medulloblastoma Immunotherapy Program
Mar 15, 2016: FDA Grants Second Orphan Designation For VAL-083
Feb 19, 2016: Novogen Patent Covering Trilexium Has Been Proceeded To Grant
Nov 11, 2015: DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Promising Potential Treatment for Pediatric Brain Tumors
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 95

LIST OF TABLES

Number of Products under Development for Medulloblastoma, H2 2016
Number of Products under Development for Medulloblastoma - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Medulloblastoma - Pipeline by Bayer AG, H2 2016
Medulloblastoma - Pipeline by DelMar Pharmaceuticals Inc, H2 2016
Medulloblastoma - Pipeline by Ignyta Inc, H2 2016
Medulloblastoma - Pipeline by IMPACT Therapeutics Inc, H2 2016
Medulloblastoma - Pipeline by Lipocure Ltd, H2 2016
Medulloblastoma - Pipeline by MacroGenics Inc, H2 2016
Medulloblastoma - Pipeline by NewLink Genetics Corp, H2 2016
Medulloblastoma - Pipeline by Novogen Ltd, H2 2016
Medulloblastoma - Pipeline by Progenics Pharmaceuticals Inc, H2 2016
Medulloblastoma - Pipeline by Stemline Therapeutics Inc, H2 2016
Medulloblastoma - Pipeline by ThromboGenics NV, H2 2016
Medulloblastoma - Pipeline by VBI Vaccines Inc, H2 2016
Medulloblastoma - Pipeline by Vyriad Inc, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Medulloblastoma - Dormant Projects, H2 2016 86

LIST OF FIGURES

Number of Products under Development for Medulloblastoma, H2 2016
Number of Products under Development for Medulloblastoma - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Ask Your Question

Medulloblastoma - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: